Adamis Pharmaceuticals (ADMP) has been fairly quiet since the company received ZIMHI's Complete Response Letter "CRL" from the FDA back on November 22th. ZIMHI is the company's high-dose naloxone injection candidate as a rescue treatment of opioid overdose. Prior to February 19th, the company's only communication has been a partial update back in December that informed investors that the company plans to have their Type A meeting with FDA and that the company will update investors when they feel like it was necessary. During this time, ADMP investors were forced to sit and